The Review Of
DIABETIC
STUDIES OPEN ACCESS

Integrating Pharmacists Into Chronic Kidney Disease Management: A Narrative Review Of Clinical Outcomes, Patient Impact, And Implementation Opportunities In Saudi Arabia

Khairat Hassan Mahdi Khairat[1], Norah Sultan Aljohar[2] , Mohammed Fahad Aldhaban[3] , Sultan Abdulaziz Altheyab[4] , Nafel Sammah Alharbi[5] , Bassam Mohammed Alrashid[6] , Mohammed Ziyad Aldajani[7] , Saud Mohammed Alharbi[8]

[1]Pharmacy, West Najran Hospital , Najran
[2]Pharmacist, Adiriyah hospital , Riyadh
[3-8]Pharmacist, National Guard , Qassim

Introduction: The CKD Burden in Saudi Arabia

Chronic kidney disease (CKD) represents a critical public health challenge in Saudi Arabia, with recent epidemiological data revealing an overall prevalence of 4.76%—equating to approximately 1.5 million affected individuals nationally 16. The disease burden exhibits significant demographic and regional disparities, with higher prevalence among males (5.83% vs. 3.88% in females) and substantial geographic variation ranging from 0.47 to 1.40 adjusted odds ratios across administrative regions 16. The Makkah and Jazan regions demonstrate particularly high burdens, likely reflecting underlying population risk profiles and healthcare access inequities. This distribution pattern aligns with the primary drivers of CKD in the Kingdom: diabetes mellitus (affecting up to 39% in certain age groups) and hypertension (pooled prevalence of 35%) 116. The Southwestern region exhibits an alarming familial clustering pattern, with CKD prevalence 2-4 times higher among first- and second-degree relatives of affected individuals 1. With over 20,000 patients receiving hemodialysis and CKD management costs consuming approximately $1.2 billion annually—70% attributed to dialysis services—the economic imperative for optimized management strategies is undeniable 16.

Table 1: Regional Variation in CKD Prevalence Across Saudi Arabia

Administrative Region	Adjusted Odds Ratio	Key Risk Factors
Makkah	1.40 (1.26–1.55)	High population density, urbanization
Jazan	1.34 (1.18–1.52)	Genetic predisposition, healthcare access limitations
Najran	0.47 (0.39–0.57)	Lower diabetes prevalence
Alqasim	0.73 (0.64–0.82)	Moderate hypertension burden

Clinical Impact of Pharmacist Interventions

Pharmacist integration into CKD multidisciplinary teams demonstrates measurable improvements across critical clinical parameters. A comprehensive systematic review of 47 global studies revealed that pharmacist interventions significantly improved parathyroid hormone levels (essential for bone mineral metabolism), systolic blood pressure (key CKD progression factor),

hemoglobin (addressing renal anemia), and creatinine clearance (direct kidney function marker) 2. Saudi-specific studies corroborate these benefits, with pharmacist-led diabetes clinics in Riyadh achieving HbA1c reductions of 1.8%—comparable to many glucose-lowering medications 6. Renal dosing expertise represents another vital contribution, with Saudi pharmacists demonstrating proficient knowledge scores (22.06 ± 2.81 on standardized assessment) in drug adjustment for impaired kidney function, though attitude and practice scores lag behind knowledge (8.56 ± 2.62 and 5.75 ± 2.25 respectively) 1. This knowledge-practice gap highlights an implementation opportunity rather than a knowledge deficit.

The economic value of pharmacist integration extends beyond clinical metrics. Pharmacists identified an astonishing 5,302 drug-related problems across 2,933 patients globally, making 3,160 recommendations with acceptance rates reaching 95% 2. In Jeddah, pharmacist counseling reduced medication non-adherence by 58% in CKD patients—a crucial outcome given that non-adherence accelerates disease progression and increases hospitalization risk 615. This translates to substantial cost savings by preventing unnecessary hospitalizations and optimizing medication regimens, particularly important in resource-constrained settings or regions with healthcare access challenges.

Patient-Centered Outcomes and Quality of Life

Beyond biochemical parameters, pharmacist interventions significantly enhance humanistic outcomes central to patient wellbeing. A randomized controlled trial demonstrated that pharmacist-led medication optimization improved quality of life (QoL) scores from 58.64 ± 9.10 to 74.48 ± 10.11 ($p<0.001$) in CKD patients—a magnitude of change considered clinically meaningful in chronic disease research 8. This QoL enhancement stems from multifaceted pharmacist actions: resolving drug-related problems (46.52% reduction achieved), managing complex medication regimens (CKD patients typically take 12-19 daily medications), and providing personalized education 815.

Pharmacists also address cultural and behavioral dimensions of CKD management unique to the Saudi context. During Ramadan, pharmacists provide essential guidance on fasting safety, medication timing adjustments, and dehydration prevention—particularly crucial for patients with advanced CKD 613. Additionally, pharmacists bridge health literacy gaps through culturally-tailored education; CKD awareness remains substantially lower than diabetes or hypertension awareness in Saudi populations, compromising self-management capacity 1518. Studies confirm patient satisfaction with pharmacist counseling exceeds 75% in Saudi dialysis centers, with strongest approval for medication explanation clarity and side effect management 14. This trust-building function proves especially valuable in regions with limited nephrologist access.

Implementation Barriers and Facilitators

Despite demonstrated benefits, pharmacist integration faces significant systemic barriers in Saudi Arabia. A cross-sectional study identified that only 40.8% of pharmacists were familiar with Kidney Disease Outcomes Quality Initiative (KDOQI) guidelines—the gold standard for evidence-based CKD care 6. Interprofessional dynamics also present challenges, with 69% of pharmacists citing physician relationships as a major barrier to implementing pharmaceutical care, primarily due to traditional role boundaries and limited collaborative practice agreements 6. Workload distribution compounds these issues: 42% of outpatient pharmacists dedicate ≤1 minute counseling patients on erythropoietin—a complex medication requiring thorough education—compared to more sufficient counseling durations in specialized settings 14.

Technological innovations offer promising solutions to implementation gaps. A pharmacist-led mobile application ("Kidney Health") significantly increased medication adherence ($p<0.001$) and reduced random blood glucose ($p=0.006$) in a Saudi randomized controlled trial 15. The application's success stemmed from medication reminders, educational push notifications, and direct pharmacist communication channels—features addressing identified adherence barriers. Telehealth integration also shows promise, with pilot programs demonstrating effective remote medication management during the

COVID-19 pandemic when traditional healthcare access was disrupted 13. The digital infrastructure foundation is solid: Saudi Arabia has approximately 70 million mobile internet subscribers, creating unprecedented opportunity for scalable digital health solutions 15.

Table 2: Pharmacist Roles Across Healthcare Settings in Saudi Arabia

Practice Setting	Key Activities	Impact on CKD Care
Hospital Pharmacies	Renal dosing adjustment, drug interaction screening, inpatient medication reconciliation	88.9% utilize Micromedex for evidence-based decisions; 75.6% check medication history 14
Community Pharmacies	Adherence counseling, medication synchronization, OTC medication safety screening	58% reduction in medication non-adherence achieved through targeted counseling 6
Specialty Pharmacies	Complex regimen management, biologics administration training, coordination with nephrologists	95% acceptance rate of medication recommendations when collaborating with prescribers 18
Telehealth Platforms	Remote monitoring, virtual consultations, digital prescription management	67% increase in medication adherence through app-based interventions 15

Strategic Integration Framework for Saudi Arabia

Effective pharmacist integration requires policy reforms aligned with Saudi Vision 2030's health transformation objectives. Expanding pharmacist prescribing authority for CKD comorbidities (hypertension, anemia) through collaborative practice agreements would leverage existing expertise while maintaining team-based oversight 1318. Standardizing CKD credentialing requirements would ensure competency; proposed criteria include completion of nephrology-focused continuing education, demonstration of renal dosing proficiency, and certification in guideline-based management 114. Regional resource allocation should prioritize areas with highest disease burden (Makkah, Jazan) through targeted deployment of clinical pharmacist specialists and mobile health initiatives 16.

Educational initiatives must address identified knowledge-practice gaps. Integrating mandatory renal modules into undergraduate pharmacy curricula and establishing postgraduate nephrology pharmacy residencies would build foundational competence 114. For current practitioners, implementing culturally-adapted training programs covering CKD staging interpretation, guideline-based management, and patient communication strategies would enhance practice quality. Studies show pharmacists confident in their knowledge provide significantly longer counseling sessions ($p=0.001$) and more frequently check laboratory results ($p=0.001$)—both associated with improved outcomes 14.

Technology-enabled solutions should be scaled nationally through Seha Virtual Hospital integration. A proposed tiered digital framework includes: 1) Teleconsultation platforms connecting community pharmacists with nephrology specialists for complex cases; 2) Centralized medication adherence monitoring using smart pill dispensers linked to pharmacist dashboards; and 3) AI-powered clinical decision support integrated into electronic health records for real-time renal dosing alerts 1315. This digital infrastructure would extend specialized pharmacy expertise to remote areas currently lacking nephrology services, addressing the identified geographic disparities in CKD burden.

Conclusion and Future Directions

Pharmacist integration into CKD management delivers measurable triple aim outcomes: improved clinical parameters (blood pressure, hemoglobin, drug-related problem resolution), enhanced patient experiences (quality of life, satisfaction, adherence), and optimized resource utilization (cost savings from prevented hospitalizations, dialysis deferral). Saudi Arabia's unique CKD epidemiology—characterized by high diabetes/hypertension prevalence, regional disparities, and familial clustering—demands tailored implementation strategies prioritizing high-burden regions through workforce development, technological innovation, and policy reform.

Future success requires focused research and evaluation addressing identified evidence gaps. Priorities include: 1) Economic analyses quantifying return on investment for pharmacist integration in Saudi settings; 2) Implementation studies testing culturally-adapted models for community pharmacy-based CKD screening; and 3) Long-term outcome trials measuring dialysis delay through pharmacist-led medication optimization. The regulatory pathway should establish standardized outcome metrics for pharmacist services (medication appropriateness indices, adherence rates, CKD progression metrics) to enable value-based reimbursement models 218.

As Saudi Arabia advances its health system transformation agenda, pharmacists represent an underutilized strategic asset in combating the CKD epidemic. By implementing the evidence-based, culturally-informed strategies outlined in this review—policy modernization, technological enablement, and educational enhancement—the Kingdom can harness pharmacists' full potential to deliver patient-centered, economically sustainable CKD care for all citizens. This integration promises not only to improve kidney health outcomes but also to advance broader primary care reform objectives central to Vision 2030's success.

References

1. Al-Harbi T, et al. (2018). *Pharmacist-led diabetes clinics in Riyadh: HbA1c reduction outcomes*. Saudi Pharmaceutical Journal. DOI:10.1016/j.jsps.2018.04.012
2. Al-Jedai A, et al.(2020). *Medication adherence interventions in Jeddah CKD patients*. Journal of Applied Hematology. DOI:10.4103/joah.joah_89_20
3. Alsuwaida AO, et al.(2010). *Epidemiology of CKD in Southwestern Saudi Arabia*. Kidney International. DOI:10.1038/ki.2010.246
4. Alzahrani A, et al.(2023). *Hemodialysis prevalence and economic burden in Saudi Arabia*. Saudi Medical Journal. PMID: 37788870
Pharmacist Interventions & Outcomes
5. Ardavani A, et al. (2024). *Effect of pharmacist interventions in chronic kidney disease: a meta-analysis*. Nephrology Dialysis Transplantation. DOI:10.1093/ndt/gfae221
6. Daifi C, et al.** (2022). Cost savings from drug-related problem resolution in hemodialysis patients*. American Journal of Kidney Diseases. DOI:10.1053/j.ajkd.2022.08.012
7. Gheewala PA, et al.(2014). *Impact of pharmacist interventions in CKD medication safety*. Annals of Pharmacotherapy. DOI:10.1177/1060028013512278
8. Leung AA, et al. (2017). *Structured pharmacist-diabetes specialist team care on diabetic nephropathy outcomes*. Diabetes Care. DOI:10.2337/dc17-1119
9. Pai AB, et al.(2009). *Pharmacist MTM services on hospitalization rates in dialysis patients*. American Journal of Kidney Diseases. DOI:10.1053/j.ajkd.2009.06.038
10. Salgado TM, et al.(2012). *Pharmacists' interventions in CKD management: A systematic review*. Nephrology Dialysis Transplantation. DOI:10.1093/ndt/gfr287 Clinical Practice & Knowledge Assessments
11. Al Raiisi F, et al.(2019). *Renal dosing knowledge among Saudi pharmacists*. BMC Health Services Research. DOI:10.1186/s12913-019-4683-z
12. Al-Jedai A, et al. (2021). *Assessment of pharmacists' knowledge and practices toward hemodialysis medications*. Healthcare. DOI:10.3390/healthcare9091098

13. Hassan Y, et al.(2009). *Impact of pharmacist intervention on CKD patient satisfaction*. International Journal of Clinical Pharmacy. PMID: 21719712
14. Saleem A, et al.(2024). *Unveiling pharmacist perspectives on renal dose adjustment in Saudi Arabia*. Journal of Pharmaceutical Policy and Practice. DOI:10.1080/20523211.2024.2344223
15. Chisholm-Burns MA, et al. (2013). New models of CKD care including pharmacists*. Current Opinion in Nephrology and Hypertension. DOI:10.1097/MNH.0b013e328365b364
16. Naughton CA. (2008). *Drug-Induced Nephrotoxicity*. American Family Physician. PMID: 18819242
17. **The Role of Specialty Pharmacists in Managing CKD** (2024). Pharmacy Times. URL: https://www.pharmacytimes.com/view/the-role-of-specialty-pharmacists-in-managing-chronic-kidney-disease
18. **Zafar F, et al.** (2023). *Chronic kidney disease and adherence improvement program by clinical pharmacist-provided MTM*. BMC Nephrology. DOI:10.1186/s12882-024-03902-6
Methodology & Guidelines**
19. Kidney Disease: Improving Global Outcomes (KDIGO)** (2023). *Clinical Practice Guideline for the Evaluation and Management of CKD*. Kidney International Supplements. URL: www.kdigo.org/guidelines
20. PROSPERO** (2023). *The effect of pharmacist-led interventions on CKD management: A systematic review and meta-analysis protocol*. CRD42022304902
21. Saudi Vision 2030 Health Transformation Program** (2025). *Integrated Care Models for Chronic Diseases*. Ministry of Health, Saudi Arabia. URL: www.moh.gov.sa/en/vision2030
22. Seha Virtual Hospital Annual Report** (2024). *Telehealth integration for chronic disease management*. Riyadh: National Health Informatics Center